Periprosthetic Joint Infection

Results from a large cohort study showed low-dose aspirin may be a safe and effective prophylaxis for the prevention of venous thromboembolism following total knee arthroplasty.

Patients who underwent two-stage revision total hip arthroplasty for periprosthetic joint infection had a minimum 2-year infection-free survivorship of 73.8% and improved patient-reported outcomes at midterm to long-term follow-up.

Published results showed antibiotic-loaded bone cement may not be warranted for prophylaxis with total knee arthroplasty due to the additional cost and similar rates of revision for periprosthetic joint infection vs. plain bone cement.

OsteoRemedies LLC announced FDA clearance for expanded indications of its Spectrum GV dual antibiotic bone cement for the use in revision total hip arthroplasty procedures, according to a press release.

Postoperative chemotherapy may be associated with increased risk of periprosthetic joint infection after total joint arthroplasty, according to published results.

A 12-week course of suppressive antibiotic therapy for periprosthetic joint infections did not show an overall benefit, but it may be more effective among patients in the United States who have higher treatment failure rates, data show.

Published results showed extended oral antibiotic prophylaxis was not associated with a reduced risk of periprosthetic joint infection at 90 days or 1 year among patients who underwent total hip or total knee arthroplasty.

According to published results, use of porous tantalum tibial metaphyseal cones in revision total knee arthroplasty was associated with durable survivorship at 10 years and low rates of implant removal.

Although the use of computer navigation and robotic assistance yielded longer operative times in total joint arthroplasty, published results showed these methods had no association with increased risk of periprosthetic joint infection.

Results from this prospective quality control study showed patients who received intrawound vancomycin powder had higher rates of periprosthetic joint infection and reoperations vs. patients who did not receive intrawound vancomycin powder.